September 12, 2016 – Plaintiffs Illumina, Inc. and Illumina Cambridge Ltd. (collectively, “Illumina”) were granted a preliminary injunction barring Defendants Qiagen, N.V., Qiagen GmbH, Qiagen Gaithersburg, Inc., Qiagen Sciences, LLC, Qiagen Inc. (USA), Qiagen Redwood City, Inc., and Intelligent Bio-Systems, Inc. from selling their DNA sequencing equipment. The Court found that Illumina was likely to succeed on the merits in part because the validity of the patent-at-issue, U.S. Patent No. 7,566,537 (entitled “Labelled Nucleotides”) had recently been upheld by the Patent Trial and Appeal Board and affirmed by the Federal Circuit. The case is No. C 16-02788 in the United States District Court for the Northern District of California.
By: Katherine E. Adams